Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer

Trial Profile

A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms JAVELIN Solid Tumor Japan
  • Sponsors Merck KGaA; Merck Serono
  • Most Recent Events

    • 21 Oct 2019 Status changed from active, no longer recruiting to completed.
    • 25 Sep 2019 Results assessing pharmacokinetic/ pharmacodynamic analyses for avelumab comparing weight-based dosing from 3 clinical trials (NCT01772004, NCT01943461, and NCT02155647) published in the Clinical Pharmacology and Therapeutics
    • 17 Sep 2019 Planned End Date changed from 30 Aug 2019 to 30 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top